Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Chemoprophylaxis vaccination: Phase 1 study to explore stage-specific immunity to Plasmodium falciparum in U.S. adults.

Healy SA, Murphy SC, Hume JCC, Shelton L, Kuntz S, Van Voorhis WC, Moodie Z, Metch B, Wang R, Silver-Brace T, Fishbaugher M, Kennedy M, Finney OC, Chaturvedi R, Hobbs CV, Warner-Lubin M, Talley AK, Wong-Madden S, Stuart K, Wald A, Kappe SH, Kublin JG, Duffy PE.

Clin Infect Dis. 2019 Oct 17. pii: ciz1010. doi: 10.1093/cid/ciz1010. [Epub ahead of print]

PMID:
31621832
2.

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial.

Pantaleo G, Janes H, Karuna S, Grant S, Ouedraogo GL, Allen M, Tomaras GD, Frahm N, Montefiori DC, Ferrari G, Ding S, Lee C, Robb ML, Esteban M, Wagner R, Bart PA, Rettby N, McElrath MJ, Gilbert PB, Kublin JG, Corey L; NIAID HIV Vaccine Trials Network.

Lancet HIV. 2019 Oct 7. pii: S2352-3018(19)30262-0. doi: 10.1016/S2352-3018(19)30262-0. [Epub ahead of print]

3.

Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa.

Gray GE, Huang Y, Grunenberg N, Laher F, Roux S, Andersen-Nissen E, De Rosa SC, Flach B, Randhawa AK, Jensen R, Swann EM, Bekker LG, Innes C, Lazarus E, Morris L, Mkhize NN, Ferrari G, Montefiori DC, Shen X, Sawant S, Yates N, Hural J, Isaacs A, Phogat S, DiazGranados CA, Lee C, Sinangil F, Michael NL, Robb ML, Kublin JG, Gilbert PB, McElrath MJ, Tomaras GD, Corey L.

Sci Transl Med. 2019 Sep 18;11(510). pii: eaax1880. doi: 10.1126/scitranslmed.aax1880.

PMID:
31534016
4.

Competing biomedical HIV prevention strategies: potential cost-effectiveness of HIV vaccines and PrEP in Seattle, WA.

Adamson B, Garrison L, Barnabas RV, Carlson JJ, Kublin J, Dimitrov D.

J Int AIDS Soc. 2019 Aug;22(8):e25373. doi: 10.1002/jia2.25373.

5.

Vaginal practices among women at risk for HIV acquisition in Soweto, South Africa.

Lazarus E, Otwombe K, Dietrich J, Andrasik MP, Morgan CA, Kublin JG, Gray GE, Isaacs AJ, Laher F.

South Afr J HIV Med. 2019 Jun 20;20(1):866. doi: 10.4102/sajhivmed.v20i1.866. eCollection 2019.

6.

Daily Vaginal Swabs and Mobile Phone Sex Report for Assessing HIV Virion Exposure Prospectively Among a Cohort of Young Sexually Active Women in South Africa (HVTN 915).

Lemos MP, Lazarus E, Isaacs A, Dietrich J, Morgan C, Huang Y, Grove D, Andrasik M, Laher F, Hural J, Chung E, Dragavon J, Puren A, Gulati RK, Coombs R, McElrath MJ, Gray G, Kublin JG.

J Acquir Immune Defic Syndr. 2019 Jun 1;81(2):e39-e48. doi: 10.1097/QAI.0000000000002015.

PMID:
31095007
7.

Beyond Blood Smears: Qualification of Plasmodium 18S rRNA as a Biomarker for Controlled Human Malaria Infections.

Seilie AM, Chang M, Hanron AE, Billman ZP, Stone BC, Zhou K, Olsen TM, Daza G, Ortega J, Cruz KR, Smith N, Healy SA, Neal J, Wallis CK, Shelton L, Mankowski TV, Wong-Madden S, Mikolajczak SA, Vaughan AM, Kappe SHI, Fishbaugher M, Betz W, Kennedy M, Hume JCC, Talley AK, Hoffman SL, Chakravarty S, Sim BKL, Richie TL, Wald A, Plowe CV, Lyke KE, Adams M, Fahle GA, Cowan EP, Duffy PE, Kublin JG, Murphy SC.

Am J Trop Med Hyg. 2019 Jun;100(6):1466-1476. doi: 10.4269/ajtmh.19-0094.

8.

Exploring Ethical Concerns About Human Challenge Studies: A Qualitative Study of Controlled Human Malaria Infection Study Participants' Motivations and Attitudes.

Kraft SA, Duenas DM, Kublin JG, Shipman KJ, Murphy SC, Shah SK.

J Empir Res Hum Res Ethics. 2019 Feb;14(1):49-60. doi: 10.1177/1556264618820219. Epub 2018 Dec 26.

PMID:
30585505
9.

Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy.

Whitney JB, Lim SY, Osuna CE, Kublin JL, Chen E, Yoon G, Liu PT, Abbink P, Borducci EN, Hill A, Lewis MG, Geleziunas R, Robb ML, Michael NL, Barouch DH.

Nat Commun. 2018 Dec 21;9(1):5429. doi: 10.1038/s41467-018-07881-9.

10.

Publisher Correction: Evidence that CD32a does not mark the HIV-1 latent reservoir.

Osuna CE, Lim SY, Kublin JL, Apps R, Chen E, Mota TM, Huang SH, Ren Y, Bachtel ND, Tsibris AM, Ackerman ME, Jones RB, Nixon DF, Whitney JB.

Nature. 2018 Nov;563(7733):E33. doi: 10.1038/s41586-018-0611-3.

PMID:
30315222
11.

Evidence that CD32a does not mark the HIV-1 latent reservoir.

Osuna CE, Lim SY, Kublin JL, Apps R, Chen E, Mota TM, Huang SH, Ren Y, Bachtel ND, Tsibris AM, Ackerman ME, Jones RB, Nixon DF, Whitney JB.

Nature. 2018 Sep;561(7723):E20-E28. doi: 10.1038/s41586-018-0495-2. Epub 2018 Sep 19. No abstract available. Erratum in: Nature. 2018 Nov;563(7733):E33.

12.

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.

Bekker LG, Moodie Z, Grunenberg N, Laher F, Tomaras GD, Cohen KW, Allen M, Malahleha M, Mngadi K, Daniels B, Innes C, Bentley C, Frahm N, Morris DE, Morris L, Mkhize NN, Montefiori DC, Sarzotti-Kelsoe M, Grant S, Yu C, Mehra VL, Pensiero MN, Phogat S, DiazGranados CA, Barnett SW, Kanesa-Thasan N, Koutsoukos M, Michael NL, Robb ML, Kublin JG, Gilbert PB, Corey L, Gray GE, McElrath MJ; HVTN 100 Protocol Team.

Lancet HIV. 2018 Jul;5(7):e366-e378. doi: 10.1016/S2352-3018(18)30071-7. Epub 2018 Jun 18.

13.

Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study.

de Montigny S, Adamson BJS, Mâsse BR, Garrison LP Jr, Kublin JG, Gilbert PB, Dimitrov DT.

Sci Rep. 2018 Apr 17;8(1):6066. doi: 10.1038/s41598-018-24268-4.

14.

Mobile Phone Questionnaires for Sexual Risk Data Collection Among Young Women in Soweto, South Africa.

Dietrich JJ, Lazarus E, Andrasik M, Hornschuh S, Otwombe K, Morgan C, Isaacs AJ, Huang Y, Laher F, Kublin JG, Gray GE; HVTN 915 study team.

AIDS Behav. 2018 Jul;22(7):2312-2321. doi: 10.1007/s10461-018-2080-y.

15.

Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials.

Gilbert PB, Juraska M, deCamp AC, Karuna S, Edupuganti S, Mgodi N, Donnell DJ, Bentley C, Sista N, Andrew P, Isaacs A, Huang Y, Zhang L, Capparelli E, Kochar N, Wang J, Eshleman SH, Mayer KH, Magaret CA, Hural J, Kublin JG, Gray G, Montefiori DC, Gomez MM, Burns DN, McElrath J, Ledgerwood J, Graham BS, Mascola JR, Cohen M, Corey L.

Stat Commun Infect Dis. 2017 Jan;9(1). pii: 20160001. doi: 10.1515/scid-2016-0001. Epub 2017 Jun 6.

16.

A Randomized Trial Evaluating the Prophylactic Activity of DSM265 Against Preerythrocytic Plasmodium falciparum Infection During Controlled Human Malarial Infection by Mosquito Bites and Direct Venous Inoculation.

Murphy SC, Duke ER, Shipman KJ, Jensen RL, Fong Y, Ferguson S, Janes HE, Gillespie K, Seilie AM, Hanron AE, Rinn L, Fishbaugher M, VonGoedert T, Fritzen E, Kappe SH, Chang M, Sousa JC, Marcsisin SR, Chalon S, Duparc S, Kerr N, Möhrle JJ, Andenmatten N, Rueckle T, Kublin JG.

J Infect Dis. 2018 Feb 14;217(5):693-702. doi: 10.1093/infdis/jix613. Erratum in: J Infect Dis. 2018 Jul 2;218(3):508.

17.

Utilizing gnotobiotic models to inform the role of the microbiome in vaccine response heterogeneity.

Cram JA, Hager KW, Kublin JG.

Curr Opin HIV AIDS. 2018 Jan;13(1):1-8. doi: 10.1097/COH.0000000000000422. Review.

PMID:
29176431
18.

Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120.

deCamp AC, Rolland M, Edlefsen PT, Sanders-Buell E, Hall B, Magaret CA, Fiore-Gartland AJ, Juraska M, Carpp LN, Karuna ST, Bose M, LePore S, Miller S, O'Sullivan A, Poltavee K, Bai H, Dommaraju K, Zhao H, Wong K, Chen L, Ahmed H, Goodman D, Tay MZ, Gottardo R, Koup RA, Bailer R, Mascola JR, Graham BS, Roederer M, O'Connell RJ, Michael NL, Robb ML, Adams E, D'Souza P, Kublin J, Corey L, Geraghty DE, Frahm N, Tomaras GD, McElrath MJ, Frenkel L, Styrchak S, Tovanabutra S, Sobieszczyk ME, Hammer SM, Kim JH, Mullins JI, Gilbert PB.

PLoS One. 2017 Nov 17;12(11):e0185959. doi: 10.1371/journal.pone.0185959. eCollection 2017.

19.

Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization.

Rademeyer C, Korber B, Seaman MS, Giorgi EE, Thebus R, Robles A, Sheward DJ, Wagh K, Garrity J, Carey BR, Gao H, Greene KM, Tang H, Bandawe GP, Marais JC, Diphoko TE, Hraber P, Tumba N, Moore PL, Gray GE, Kublin J, McElrath MJ, Vermeulen M, Middelkoop K, Bekker LG, Hoelscher M, Maboko L, Makhema J, Robb ML, Karim SA, Karim QA, Kim JH, Hahn BH, Gao F, Swanstrom R, Morris L, Montefiori DC, Williamson C.

PLoS Pathog. 2017 Sep 25;13(9):e1006641. doi: 10.1371/journal.ppat.1006641. eCollection 2017 Sep.

20.

Zika virus research models.

Kublin JL, Whitney JB.

Virus Res. 2018 Aug 2;254:15-20. doi: 10.1016/j.virusres.2017.07.025. Epub 2017 Aug 12. Review.

21.

The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United States.

Adamson BJS, Carlson JJ, Kublin JG, Garrison LP.

Vaccines (Basel). 2017 May 24;5(2). pii: E13. doi: 10.3390/vaccines5020013.

22.

Multiplex, DNase-free one-step reverse transcription PCR for Plasmodium 18S rRNA and spliced gametocyte-specific mRNAs.

Hanron AE, Billman ZP, Seilie AM, Olsen TM, Fishbaugher M, Chang M, Rueckle T, Andenmatten N, Greenhouse B, Arinaitwe E, Rek J, Das S, Domingo GJ, Shipman K, Kappe SH, Kublin JG, Murphy SC.

Malar J. 2017 May 19;16(1):208. doi: 10.1186/s12936-017-1863-3.

23.

Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects.

Kublin JG, Mikolajczak SA, Sack BK, Fishbaugher ME, Seilie A, Shelton L, VonGoedert T, Firat M, Magee S, Fritzen E, Betz W, Kain HS, Dankwa DA, Steel RW, Vaughan AM, Noah Sather D, Murphy SC, Kappe SH.

Sci Transl Med. 2017 Jan 4;9(371). pii: eaad9099. doi: 10.1126/scitranslmed.aad9099.

PMID:
28053159
24.

A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial.

Hertz T, Logan MG, Rolland M, Magaret CA, Rademeyer C, Fiore-Gartland A, Edlefsen PT, DeCamp A, Ahmed H, Ngandu N, Larsen BB, Frahm N, Marais J, Thebus R, Geraghty D, Hural J, Corey L, Kublin J, Gray G, McElrath MJ, Mullins JI, Gilbert PB, Williamson C.

Vaccine. 2016 Nov 11;34(47):5792-5801. doi: 10.1016/j.vaccine.2016.09.054. Epub 2016 Oct 15.

25.

Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants.

Churchyard G, Mlisana K, Karuna S, Williamson AL, Williamson C, Morris L, Tomaras GD, De Rosa SC, Gilbert PB, Gu N, Yu C, Mkhize NN, Hermanus T, Allen M, Pensiero M, Barnett SW, Gray G, Bekker LG, Montefiori DC, Kublin J, Corey L.

PLoS One. 2016 Sep 1;11(9):e0161753. doi: 10.1371/journal.pone.0161753. eCollection 2016.

26.

Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization.

Rademeyer C, Korber B, Seaman MS, Giorgi EE, Thebus R, Robles A, Sheward DJ, Wagh K, Garrity J, Carey BR, Gao H, Greene KM, Tang H, Bandawe GP, Marais JC, Diphoko TE, Hraber P, Tumba N, Moore PL, Gray GE, Kublin J, McElrath MJ, Vermeulen M, Middelkoop K, Bekker LG, Hoelscher M, Maboko L, Makhema J, Robb ML, Abdool Karim S, Abdool Karim Q, Kim JH, Hahn BH, Gao F, Swanstrom R, Morris L, Montefiori DC, Williamson C.

PLoS Pathog. 2016 Jul 19;12(7):e1005742. doi: 10.1371/journal.ppat.1005742. eCollection 2016 Jul. Erratum in: PLoS Pathog. 2017 Sep 25;13(9):e1006641.

27.

Lower Viral Loads and Slower CD4+ T-Cell Count Decline in MRKAd5 HIV-1 Vaccinees Expressing Disease-Susceptible HLA-B*58:02.

Leitman EM, Hurst J, Mori M, Kublin J, Ndung'u T, Walker BD, Carlson J, Gray GE, Matthews PC, Frahm N, Goulder PJ.

J Infect Dis. 2016 Aug 1;214(3):379-89. doi: 10.1093/infdis/jiw093. Epub 2016 Mar 6.

28.

Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models.

Dimitrov D, Kublin JG, Ramsey S, Corey L.

EBioMedicine. 2015 Nov 5;2(12):2062-9. doi: 10.1016/j.ebiom.2015.11.009. eCollection 2015 Dec.

29.

Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.

Huang Y, DiazGranados C, Janes H, Huang Y, deCamp AC, Metch B, Grant S, Sanchez B, Phogat S, Koutsoukos M, Kanesa-Thasan N, Bourguignon P, Collard A, Buchbinder S, Tomaras GD, McElrath J, Gray G, Kublin JG, Corey L, Gilbert PB.

Curr Opin Virol. 2016 Apr;17:57-65. doi: 10.1016/j.coviro.2016.01.007. Epub 2016 Jan 29. Review.

30.

Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men.

Moodie Z, Metch B, Bekker LG, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S, Mngadi K, Innes C, Mathebula M, Allen M, Bentley C, Gilbert PB, Robertson M, Kublin J, Corey L, Gray GE.

PLoS One. 2015 Sep 14;10(9):e0137666. doi: 10.1371/journal.pone.0137666. eCollection 2015.

31.

Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.

Huang Y, Follmann D, Nason M, Zhang L, Huang Y, Mehrotra DV, Moodie Z, Metch B, Janes H, Keefer MC, Churchyard G, Robb ML, Fast PE, Duerr A, McElrath MJ, Corey L, Mascola JR, Graham BS, Sobieszczyk ME, Kublin JG, Robertson M, Hammer SM, Gray GE, Buchbinder SP, Gilbert PB.

PLoS One. 2015 Sep 2;10(9):e0136626. doi: 10.1371/journal.pone.0136626. eCollection 2015.

32.

Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials.

Jin X, Morgan C, Yu X, DeRosa S, Tomaras GD, Montefiori DC, Kublin J, Corey L, Keefer MC; NIAID HIV Vaccine Trials Network.

Vaccine. 2015 May 11;33(20):2347-53. doi: 10.1016/j.vaccine.2015.03.036. Epub 2015 Mar 25.

33.

Persistence of Sulfadoxine-Pyrimethamine Resistance Despite Reduction of Drug Pressure in Malawi.

Artimovich E, Schneider K, Taylor TE, Kublin JG, Dzinjalamala FK, Escalante AA, Plowe CV, Laufer MK, Takala-Harrison S.

J Infect Dis. 2015 Sep 1;212(5):694-701. doi: 10.1093/infdis/jiv078. Epub 2015 Feb 11.

34.

A new model for catalyzing translational science: the early stage investigator mentored research scholar program in HIV vaccines.

Adamson BJ, Fuchs JD, Sopher CJ, Flood DM, Johnson RP, Haynes BF, Kublin JG; NIAID HIV Vaccine Trials Network.

Clin Transl Sci. 2015 Apr;8(2):166-8. doi: 10.1111/cts.12249. Epub 2014 Dec 30.

35.

Attracting, equipping and retaining young medical doctors in HIV vaccine science in South Africa.

Flood D, Wallace M, Bloch K, Kublin J, Bekker LG.

South Afr J HIV Med. 2015;16(1). pii: 364. Epub 2015 Nov 19.

36.

Generation and evaluation of clade C simian-human immunodeficiency virus challenge stocks.

Chang HW, Tartaglia LJ, Whitney JB, Lim SY, Sanisetty S, Lavine CL, Seaman MS, Rademeyer C, Williamson C, Ellingson-Strouss K, Stamatatos L, Kublin J, Barouch DH.

J Virol. 2015 Feb;89(4):1965-74. doi: 10.1128/JVI.03279-14. Epub 2014 Dec 3.

37.

Use of placebos in Phase 1 preventive HIV vaccine clinical trials.

Huang Y, Karuna ST, Janes H, Frahm N, Nason M, Edlefsen PT, Kublin JG, Corey L, McElrath MJ, Gilbert PB.

Vaccine. 2015 Feb 4;33(6):749-52. doi: 10.1016/j.vaccine.2014.10.017. Epub 2014 Oct 23.

38.

Tuberculosis vaccines and prevention of infection.

Hawn TR, Day TA, Scriba TJ, Hatherill M, Hanekom WA, Evans TG, Churchyard GJ, Kublin JG, Bekker LG, Self SG.

Microbiol Mol Biol Rev. 2014 Dec;78(4):650-71. doi: 10.1128/MMBR.00021-14. Review.

39.

Safety and comparability of controlled human Plasmodium falciparum infection by mosquito bite in malaria-naïve subjects at a new facility for sporozoite challenge.

Talley AK, Healy SA, Finney OC, Murphy SC, Kublin J, Salas CJ, Lundebjerg S, Gilbert P, Van Voorhis WC, Whisler J, Wang R, Ockenhouse CF, Heppner DG, Kappe SH, Duffy PE.

PLoS One. 2014 Nov 18;9(11):e109654. doi: 10.1371/journal.pone.0109654. eCollection 2014.

40.

Enhancing diversity in the public health research workforce: the research and mentorship program for future HIV vaccine scientists.

Sopher CJ, Adamson BJ, Andrasik MP, Flood DM, Wakefield SF, Stoff DM, Cook RS, Kublin JG, Fuchs JD.

Am J Public Health. 2015 Apr;105(4):823-30. doi: 10.2105/AJPH.2014.302076. Epub 2014 Aug 14.

41.

Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses.

Hopkins KL, Laher F, Otwombe K, Churchyard G, Bekker LG, DeRosa S, Nchabeleng M, Mlisana K, Kublin J, Gray G.

PLoS One. 2014 Aug 4;9(8):e103446. doi: 10.1371/journal.pone.0103446. eCollection 2014.

42.

The immune space: a concept and template for rationalizing vaccine development.

Manrique A, Adams E, Barouch DH, Fast P, Graham BS, Kim JH, Kublin JG, McCluskey M, Pantaleo G, Robinson HL, Russell N, Snow W, Johnston MI.

AIDS Res Hum Retroviruses. 2014 Nov;30(11):1017-22. doi: 10.1089/AID.2014.0040. Epub 2014 Jun 26.

43.

HIV-1 infection and antibodies to Plasmodium falciparum in adults.

Hasang W, Dembo EG, Wijesinghe R, Molyneux ME, Kublin JG, Rogerson S.

J Infect Dis. 2014 Nov 1;210(9):1407-14. doi: 10.1093/infdis/jiu262. Epub 2014 May 3.

PMID:
24795481
44.

Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.

Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker LG, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S, Mngadi K, Innes C, Mathebula M, Allen M, McElrath MJ, Robertson M, Kublin J, Corey L; HVTN 503/Phambili study team.

Lancet Infect Dis. 2014 May;14(5):388-96. doi: 10.1016/S1473-3099(14)70020-9. Epub 2014 Feb 20.

45.

Understanding HIV epidemics: aggregate viral load metrics and 'smoking guns'.

Abu-Raddad LJ, Barnabas RV, Janes H, Weiss HA, Kublin JG, Longini IM Jr, Wasserheit JN.

AIDS. 2013 Nov 13;27(17):2826-7. doi: 10.1097/QAD.0000000000000002. No abstract available.

PMID:
24384634
46.

The HVTN503/Phambili HIV vaccine trial: a comparison of younger and older participants.

Volk JE, Hessol NA, Gray GE, Kublin JG, Churchyard GJ, Mlisana K, Nchabeleng M, Buchbinder SP, Bekker LG.

Int J STD AIDS. 2014 Apr;25(5):332-40. doi: 10.1177/0956462413506892. Epub 2013 Oct 8.

47.

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, Frahm N, Hural J, Anude C, Graham BS, Enama ME, Adams E, DeJesus E, Novak RM, Frank I, Bentley C, Ramirez S, Fu R, Koup RA, Mascola JR, Nabel GJ, Montefiori DC, Kublin J, McElrath MJ, Corey L, Gilbert PB; HVTN 505 Study Team.

N Engl J Med. 2013 Nov 28;369(22):2083-92. doi: 10.1056/NEJMoa1310566. Epub 2013 Oct 7.

48.

Lessons learned from HIV vaccine clinical efficacy trials.

Day TA, Kublin JG.

Curr HIV Res. 2013 Sep;11(6):441-9. Review.

49.

Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load?

Abu-Raddad LJ, Barnabas RV, Janes H, Weiss HA, Kublin JG, Longini IM Jr, Wasserheit JN.

AIDS. 2013 Sep 24;27(15):2494-6. doi: 10.1097/01.aids.0000432463.23508.a2. No abstract available.

PMID:
24029738
50.

Behavioral risk assessment in HIV Vaccine Trials Network (HVTN) clinical trials: a qualitative study exploring HVTN staff perspectives.

Andrasik MP, Karuna ST, Nebergall M, Koblin BA, Kublin JG; NIAID HIV Vaccine Trials Network.

Vaccine. 2013 Sep 13;31(40):4398-405. doi: 10.1016/j.vaccine.2013.07.003. Epub 2013 Jul 13.

Supplemental Content

Loading ...
Support Center